Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

I<131> labeled anti-human neuropilin receptor-2 monoclonal antibody E4 and application thereof

A 131I-E4, monoclonal antibody technology, applied in the direction of antibodies, antibody medical ingredients, medical preparations containing active ingredients, etc., can solve the problems of lack of research and application, achieve high early diagnosis rate of tumors and monitor curative effect, and improve The effect of early diagnosis rate and monitoring curative effect, high targeting and molecular imaging efficiency

Inactive Publication Date: 2017-12-01
ZHONGSHAN HOSPITAL XIAMEN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, NRP-2 may become a new target for tumor imaging and treatment research, but there is currently a lack of corresponding research and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • I&lt;131&gt; labeled anti-human neuropilin receptor-2 monoclonal antibody E4 and application thereof
  • I&lt;131&gt; labeled anti-human neuropilin receptor-2 monoclonal antibody E4 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Embodiment one, the present invention 131 I-labeled anti-human neuropilin receptor-2 monoclonal antibody E4 was tested against the E4 antibody by the chloramine T-labeled method. 131 I mark: take E4 antibody, Na 131 I and PBS with a pH value of 7.4 were added to the EP tube, and the newly configured chloramine T was added, shaken and mixed rapidly, and after the reaction at room temperature, the newly configured reducing agent sodium metabisulfite was added to terminate the iodination reaction; As a developing agent, the labeling rate of the labeled product was determined by TLC; the above reaction solution was purified through a SephadexG25 column, and PBS with a pH value of about 7.4 was used as an eluent to obtain 131 I-E4. That is, human E4 antibody, Na 131 1, chloramine T is raw material, adopts chloramine T standard method to carry out to E4 antibody 131 I mark, after purification, get 131 I-E4. The humanized E4 antibody is obtained by RT-PCR technology to o...

Embodiment 2

[0033] Embodiment two, the present invention 131 The difference between the I-labeled anti-human neuropilin receptor-2 monoclonal antibody E4 and Example 1 is that the pH of PBS is 7.6; the reaction at room temperature is 5 minutes at room temperature. Made in this example 131 The labeling rate measured by I-E4 was compared with figure 1 No significant difference. Made in this example 131 I-E4 carries out lung cancer animal model according to embodiment method 131 The results of I-E4 radioimmunoimaging were also not significantly different from those in Examples.

[0034] In a word: after adopting above-mentioned technical scheme, the present invention 131 I-labeled anti-human neuropilin receptor-2 monoclonal antibody E4 and its application have the advantages of radionuclides and anti-tumor cell humanized monoclonal antibodies in one, targeting and molecularly displaying tumor cells. It has the advantages of high imaging efficiency, high early diagnosis rate and monitor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an I<131> labeled anti-human neuropilin receptor-2 (NRP-2) monoclonal antibody E4. The antibody E4 is labeled by I<131> through a chloramine T labeling method. The I<131>-E4 is produced through the following steps: 1) preparing the antibody E4, NaI<131>, and PBS being 7.4-7.6 in pH value, and adding the components into an EP tube, adding newly-prepared chloramine T and rapidly vibrating and uniformly mixing the liquid, performing a reaction at room temperature, and adding a newly-prepared reduction agent, sodium metabisulfite, to terminate the iodination reaction; 2) moving out the reaction liquid, and measuring the labeling rate of a labeled product through TLC, normal saline being a developing solvent; 3) treating the reaction liquid on a Sephadex G25 column to purify the reaction liquid with PBS being about 7.4 in pH value as an eluting solution to prepare I<131>-E4. Advantages of the radionuclide are integrated with the antitumor cell humanized monoclonal antibody, so that the targeting property and molecular imaging effect of the medicine are improved. The antibody E4 can increase the early-stage diagnosis rate and monitor treatment effect of positive tumor expressed by the NRP-2, has a wider available range and is suitable for imaging positive tumors expressed by the NRP-2 in all stages.

Description

technical field [0001] The present invention relates to a monoclonal antibody, in particular to a 131 I-labeled anti-human neuropilin receptor-2 monoclonal antibody E4 and its application. Background technique [0002] In human tumor cells, such as malignant glioma cells, melanoma, colorectal cancer, bladder tumor, pancreatic tumor, lung cancer, breast cancer and other malignant tumors, neuropilin receptor-2 (Neuropilins-2, NRP-2 ) showed high expression, and the expression of NRP-2 was closely related to the resistance of tumor therapy and the prognosis of patients. Therefore, NRP-2 may become a new target for tumor imaging and treatment research, but there is currently a lack of corresponding research and application. Contents of the invention [0003] The purpose of the present invention is to provide a kind of 131 I-labeled anti-human neuropilin receptor-2 monoclonal antibody E4, the purpose of the present invention is also to provide its application. [0004] To a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/10A61K39/395A61P35/00A61K101/02
CPCA61K9/0019A61K39/3955A61K51/1033
Inventor 苏新辉陈丽春颜江华王亮亮
Owner ZHONGSHAN HOSPITAL XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com